Personal Finance

Why GW Pharmaceuticals Stock Lost 17.7% in February

GWPH Chart

What happened

GW Pharmaceuticals (NASDAQ: GWPH) stock lost 17.7% in February, according to data provided by S&P Global Market Intelligence .

GWPH data by YCharts .

So what

Its stock saw big sell-offs following an announcement from GW Pharmaceuticals that one if its in-development, cannabis-derived seizure treatment drugs had not produced the expected results. The phase 2a clinical evaluation for its GWP42006 compound did not show that the drug produced effects that were significantly better than those for the the study's placebo control group.

Both groups showed a roughly 40% reduction in focal seizures, with the performance for the placebo group coming in well above expectations and falling outside of the range documented in previously published studies.

Marijuana plants growing close together.

Image source: Getty Images.

While the company was disappointed with the results for the recent GWP42006 study, it's still moving ahead with testing the compound as an epileptic seizure treatment and is also conducting trials on the drug's efficacy for treating symptoms of autism spectrum disorders.

Now what

The confounding results of GWP42006 present a significant setback for GW Pharmaceuticals, but the company is making progress on other fronts. Results from phase 3 testing for its epilepsy treatment drug Epidiolex have been very encouraging, and management expects that there is a good chance that the treatment could debut this year in the U.S. market.

GW Pharmaceuticals has big growth opportunities ahead, but it's worth keeping in mind that shares trade at lofty multiples. The company is valued at roughly 166 times forward sales -- a daunting multiple that underscores the risk of betting big on the future of marijuana-related industries.

10 stocks we like better than GW Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of March 5, 2018

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GWPH

Other Topics

Stocks

Latest Personal Finance Videos

How Student Loan Refinancing Works

Though it may be a great way to lower monthly payments, not everyone understands the student loan refinancing process. NerdWallet explains it. For more, try our refinance calculator: http://bit.ly/nerdwallet-student-loan-refinancing-calculator

Nov 25, 2019

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More